AKT1 and esophageal squamous cell carcinoma: Such approaches included medroxyprogesterone acetate,29, 30 gene therapy31 and lysophosphatidic acid,32 and some candidate drug targeting lysophosphatidic acid could even induce tumor dormancy at secondary tumor sites.33 Moreover, in our current study, application of the Akt inhibitor MK2206 was able to abrogate the invasiveness of Nm23H1-depleted ESCC cells significantly.